OmniLytics, Inc. raised 50% of its $400,000 mezzanine private placement from one investor. The company placed an estimated $700,000 in mezzanine security since 2009. The offering will remain open for a year during which at most four investors will be sought after.
OmniLytics, Inc. develops bacteriophage, i.e. good viruses that eat specific bacteria, as a natural solution for infectious disease control. The company’s bacteriophage technology is leveraged for the research and development of bacteriophage solutions for pathogen control in the agricultural, food & water, industrial, pharmaceutical, and defense markets. It received an EPA registration for its’ AgriPhage bacteria-control product line.
The company, headquartered in Sandy UT, is lead by Justin Rieber (President and CEO).